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Image in Focus
Figure 1. Gross view of the surgical specimen from an insufficient mitral valve represented by the anterior leaflet. 
A – The atrial aspect; B – The ventricular aspect. Note the diffuse thickening of the redundant leaflet with focal 
bulging towards the atrial aspect (asterisks) flagged as areas of valvar prolapse by the imaging exams. The chordae 
tendineae are also thickened. One of them shows a rounded tail end, which is characteristic of a secondary lesion 
due to its rupture (arrows); C and D – Photomicrography of the valve leaflet. In C, a central area of dense fibrous 
tissue (F) is shown, surrounded by a thick layer of loose connective tissue with myxomatous appearance (M). 
Hematoxylin-eosin stain, objective magnification 10X. In D, the valve section stained with Movat pentachrome is 
shown, revealing pale blue areas corresponding to myxomatous stroma. Black areas correspond to elastic fibers, 
focally disrupted (black arrowhead). Objective magnification 2.5X.
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Myxomatous degeneration of the cardiac valves 
(MDMV) stands for the non-inflammatory progressive 
disarray of the valve structure caused by a defect in the 
mechanical integrity of the leaflet due to the altered 
synthesis and/or remodeling by type VI collagen. 
The gross morphologic features are characterized by 
voluminous and thickened leaflets, in both longitudinal 
and transversal axes. This entity involves not only 
the valve but also the chordae tendineae that has 
also become thickened, elongated, and sometimes 
ruptured.1 Additionally, MDMV mostly involves the 
posterior leaflet, usually in the absence of commissural 
fusion and with a normal or enlarged annulus.1,2 
Histologically, MDMV is characterized by thickening 
and proliferation of the spongiosa with pooling 
of glycosaminoglycan that expands to the fibrosa, 
giving the appearance of cystic spaces and less dense 
collagen. Common alterations include fragmentation 
of the collagen of the fibrosa layer, and the presence 
of disrupted, fragmented, and granular elastic fibers 
forming an amorphous clump.3
Although the primary mechanism is uncertain, it 
is thought to happen due to an imbalance between 
synthesis and degradation of the extracellular matrix 
in which overexpression of metalloproteinases and 
cellular proliferation are involved.4 A dominant familial 
inheritance, mapped to Xq28, has been reported 
in a cohort study.5 The Marfan and Ehlers–Danlos 
syndromes are also associated with MDMV, although 
the pathogenesis is not well known. However, it 
is conceived that the genetic abnormalities are 
responsible for the defective synthesis of the elastic 
fibers and the collagen, respectively, which directly 
weakens the valve structure or indirectly alters the 
muscular contraction, placing greater stress on the 
valves, and inducing the myxomatous alterations.6 
The myxomatous valve can be distinguished from 
rheumatic valvular disease by retraction and fusion 
of the chordae, besides commissural fusion and the 
presence of inflammatory infiltration and neoformed 
vessels in the latter.6
The most frequent complication of myxomatous 
valvular disease is the mitral valve prolapse (MVP),7 
defined as the atrial bulging of the mitral leaflets of more 
than 2 mm during systole beyond the annular plane, a 
valvular thickening of ≥3 mm and/or ruptured chordae 
tendineae. In a retrospective cohort study,8 MVP was 
observed in 87.5% of the patients with myxomatous 
degeneration. Since MDMV is a histopathological 
diagnosis, its prevalence is estimated based on the MVP 
diagnosed by echocardiography which is 1%-4%, in 
the epidemiological cohorts.7,9,10 MDMV occurs more 
frequently in young females; however, the males 
are more symptomatic.6 The mitral valve represents 
more than 60% of myxomatous degenerated valves, 
followed by the aortic and tricuspid valves.8 Compared 
to control individuals, the presence of MVP leads to 
a greater degree of mitral regurgitation, which is, on 
average, trace or mild. In addition, no differences 
were observed concerning the symptoms of chest 
pain, dyspnea, or electrocardiographic abnormalities.7,8 
Therefore the association of MDMV and cardiovascular 
symptoms remains uncertain.11
The feared complication of MDMV is the 
rupture of the chordae tendineae, which leads to 
acute mitral regurgitation or the enhancement 
of pre-existing insufficiency.6 Symptoms of acute 
mitral regurgitation are of acute pulmonary edema, 
hypotension, and features consistent with cardiogenic 
shock.12 The treatment of symptomatic acute severe 
non-ischemic mitral rupture is immediate mitral valve 
surgery, which consists of implanting a prosthetic mitral 
or mitral valve repair.12 The surgical technique depends 
on the degree of valve degeneration, the dilation of 
cardiac chambers, and the experience of the surgical 
team.13,14 Complications associated with MDMV 
include infective endocarditis, sudden death, and the 
occurrence of stroke in younger patients. A higher 
prevalence (11.7%) of MVP in sudden cardiac deaths 
(SCD) compared to the general population provides 
indirect evidence of the association of MVP and SCD.15
The image above (Figure 1) is the surgical specimen 
of a 50-year-old man who was submitted to a mitral 
valve replacement. He presented to the emergency 
room complaining of fatigue and moderate exertional 
dyspnea. His medical history included systemic arterial 
hypertension, chronic atrial fibrillation, asthma, and 
diverticulitis. On the physical examination, a systolic 
regurgitation murmur was audible on the cardiac 
apex associated with bilateral pulmonary crackles and 
increased jugular venous pressure.
The echocardiography showed a normal left 
ventricular ejection fraction, normal myocardium 
thickness, a moderate to severe enlargement of the 
left cardiac chambers, and marked mitral regurgitation. 
The coronary catheterization was unremarkable.
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The patient underwent valve replacement by a 
Carpentier–Edwards bovine pericardium prosthesis. 
The postoperative period was uneventful, and he was 
discharged 3 days after surgery to an outpatient clinic 
follow-up.
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